Ozempic and Wegovy Aspiration During Anesthesia Claims

Ozempic and Wegovy contain semaglutide, which delays stomach emptying. Current U.S. prescribing information for both products reports rare postmarketing cases of pulmonary aspiration in people receiving GLP-1 medicines who underwent elective surgery or procedures requiring general anesthesia or deep sedation. In the reports, residual stomach contents were present despite reported adherence to preoperative fasting recommendations. These reports raise a safety question; they do not establish that semaglutide caused an individual event or that every patient faces the same risk.

What pulmonary aspiration means

Pulmonary aspiration occurs when material from the stomach or mouth enters the airway or lungs. Under general anesthesia or deep sedation, protective reflexes and a person’s ability to respond can be reduced. Aspiration may cause breathing complications, infection, or other serious harm and may require emergency treatment or hospitalization. Clinicians determine what happened and what treatment is needed.

What the Ozempic and Wegovy labels say

The current FDA-approved labels state that semaglutide delays gastric emptying and include warnings about pulmonary aspiration during general anesthesia or deep sedation. The labels describe rare postmarketing reports associated with elective surgeries or procedures. They also state that available data are insufficient to make recommendations on whether changing fasting instructions or temporarily stopping semaglutide would reduce retained stomach contents or aspiration risk.

Patients should tell healthcare professionals about semaglutide use before any planned surgery or procedure. Decisions about medication, fasting, anesthesia, or procedure timing belong with the treating prescriber and procedural or anesthesia team. Do not stop a prescribed medicine or change fasting instructions based on a website.

When an event may warrant legal review

A person who experienced aspiration, a cancelled or delayed procedure, emergency treatment, or a lasting complication while using semaglutide may want an individualized review. The fact that an event occurred after taking Ozempic or Wegovy is not, by itself, proof that the medicine caused it. A legal review should examine the complete record and account for other possible causes and the decisions made by the medical team.

Relevant information may include:

• The specific medication, dose, dosing dates, and prescribing history
• The procedure, anesthesia plan, fasting instructions, and what the patient reported to clinicians
• Pre-procedure assessments, anesthesia records, imaging, incident reports, and discharge records
• The timing and nature of aspiration symptoms, treatment, hospitalization, and recovery
• Other medical conditions, medicines, and potential contributing factors
• The product labeling in effect at the time and applicable state law

Preserve available records and write down the timeline while it is fresh. A lawyer can explain what records may be useful and whether the facts support additional investigation. No page or checklist can determine whether an individual has a viable claim.

How Logue Law Group reviews Ozempic and Wegovy matters

Logue Law Group handles Ozempic and Wegovy injury matters and works with leading national mass-tort firms to evaluate complex pharmaceutical cases. We review each matter individually, including medical history, medication timeline, claimed injury, potential causes, and the applicable law. A review does not mean that a claim will be accepted, filed, or successful, and no outcome is promised.

There is no universal settlement amount for a semaglutide aspiration case. Any recovery depends on the evidence, the nature and duration of the injury, causation, damages, defenses, and applicable law. Prior results do not guarantee a similar outcome.

Related Ozempic and Wegovy guides

• Ozempic and Wegovy injury claims overview
• Ileus and bowel obstruction claims
• Pancreatitis claims

Contact Logue Law Group

If you or a family member had a serious complication during or after a procedure while taking semaglutide, contact Logue Law Group to request a confidential case review. Call (412) 387-6901 or contact us online.

Medical information and legal advertising notice: This page provides general information, not medical advice or a determination of legal rights. Seek advice from qualified healthcare professionals about medicines, fasting, surgery, or symptoms. Laws and deadlines differ by jurisdiction. Contacting the firm does not by itself create an attorney-client relationship.

Sources: Current OZEMPIC prescribing information, Section 5.10; Current WEGOVY prescribing information, Section 5.10.